What Changed at 4baseCare

Every material change AI Health Index has tracked at 4baseCare: new modules, model and architecture updates, clinical evidence, regulatory status, security certifications, and integration depth. Each entry states what changed, cites its source, and carries our read on what it means for a buyer. The graded assessment of this vendor across all fifteen capability axes sits on its index profile.

Funding rounds, valuations, and awards are not product changes and are not logged here. Acquisitions appear only where there is direct product impact.

Impact

Type

1 entry

Showing changes for 4baseCare only.Show the full log

August 2026

4

4baseCare

Aug 18, 2026

MediumPartially Verified

Product / capability

4baseCare launched TARGT Indiegene V2, a cancer profiling panel expanded to cover 2,206 genes. The updated panel is positioned by the vendor as providing precision oncology insights tailored for diverse and historically underrepresented populations.

Our read

Oncologists and health systems gain access to a significantly expanded genomic panel, which the vendor positions as enabling more precise targeted therapy selection for cancer patients from diverse genetic backgrounds. Reported only in trade press so far; confirm panel specifications at source before relying on them.

Related axis: Setting and Specialty CoverageTrade pressView source